A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-Infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496 [lexgenleucel-T].

Trial Profile

A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-Infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496 [lexgenleucel-T].

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2010

At a glance

  • Drugs Lexgenleucel T (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2023 as reported by ClinicalTrials.gov.
    • 05 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top